Cell Envelope Integrity and Capsule Characterization of *Rhodotorula mucilaginosa* Strains from Clinical and Environmental Sources

Johnathan Yockey, Luke Andres, Moleigh Carson, Jeramia J. Ory, Amy J. Reese

*St. Louis College of Pharmacy, St. Louis, Missouri, USA*

**ABSTRACT**  
*Rhodotorula* yeasts are pink, encapsulated basidiomycetes isolated from a variety of environments and clinical settings. They are increasingly linked with disease, particularly central venous catheter infections and meningitis, in immunocompromised patients. Eight clinical and eight environmental strains molecularly typed as *Rhodotorula mucilaginosa* were compared to six *Cryptococcus neoformans* strains for phenotypic variability. Growth on cell integrity-challenging media suggested that *R. mucilaginosa* cells possess differences in signaling pathways, cell wall composition, or assembly and that their membranes are more susceptible to perturbations than those of *C. neoformans*. All 16 *R. mucilaginosa* strains produced urease, while none produced melanin with L-3,4-dihydroxyphenylalanine (L-DOPA) as a substrate. India ink staining reveals that clinical *R. mucilaginosa* capsules are larger than environmental capsules but that both are generally smaller than *C. neoformans* capsules. All *R. mucilaginosa* strains were resistant to fluconazole. Only two clinical strains were susceptible to voriconazole; all of the environmental strains were resistant. We generated an anticapsular antibody (Rh1) to *Rhodotorula*; Rh1 did not bind *C. neoformans* control strains, was specific to *Rhodotorula* species, and bound to all tested *Rhodotorula* strains. Binding assays performed with wheat germ agglutinin (WGA), concanavalin A (ConA), calcofluor white (CFW), and eosin Y dye (EY) cell surface probes suggested that chitin may be more accessible in *R. mucilaginosa* but that the total abundance of chitooligomers is less than in *C. neoformans*. This report describes a novel reagent that can be used to identify *Rhodotorula* species and lays the foundation for future cell envelope composition analysis.

**IMPORTANCE**  
Currently, there is very little known about the phenotypic variability within species of *Rhodotorula* strains and the role of their capsule. *Cryptococcus neoformans* has been considered the only encapsulated human fungal pathogen, but as more individuals come to live in states of immunocompromised health, they are more susceptible to fungal infections, including those by *Rhodotorula*. *R. mucilaginosa* species are some of those most commonly associated with clinical infections. We wanted to know if clinical and environmental strains of *R. mucilaginosa* demonstrated disparate capsule phenotypes. With limited antifungal options available and clinical *Rhodotorula* spp. often resistant to common antifungal drugs such as fluconazole, caspofungin (1, 2), and voriconazole (2), a better understanding of the fungal biology could inform the design and use of future antifungal drugs. The generation of an antibody specific to *Rhodotorula* fungi could be a useful diagnostic tool, and this work presents the first mention of such in the literature.

**KEYWORDS** Cryptococcus, Rhodotorula, capsule, cell wall integrity
With advances in medicine, people are living longer in immunosuppressed states, making them more susceptible to fungal infections of various types that range from mild to severe. The literature demonstrates an increasing number of reports of *Rhodotorula* spp. being isolated from patients, with *R. mucilaginosa* being the most common species. Central venous catheter (CVC) usage has been linked most extensively with fungemia in immunocompromised patients (3–6), while human immunodeficiency virus (HIV)-positive status has been linked most extensively with cases of meningitis (2, 4).

One particular challenge with *Rhodotorula* infections is efficient identification of the etiologic agent, as *Rhodotorula* species are not in the short list of those likely to cause fungal infections. A second concern is the practice of treating fungal infections with echinocandins, such as caspofungin, before complete identification has been made. This class of antifungal drugs is not effective against *Rhodotorula* and other basidiomycetes, such as *Cryptococcus neoformans* (7). Susceptibility tests have demonstrated that *Rhodotorula* species respond best to amphotericin B and flucytosine and poorly to the azoles (1, 7–10), with amphotericin B still being the primary drug of choice. Such susceptibility methods have not been employed with environmental strains.

The cells of *Rhodotorula* spp. are generally oval-shaped cells that yield pink to coral-colored colonies on standard yeast media (11). Cell shapes do seem to differ between and within *Rhodotorula* spp., with some being considerably more rod-like (12–14). Cell wall composition may play a role in these shape differences, as has been shown in other fungi and reviewed previously by Bose et al. (15). The wall composition and stability of *C. neoformans* cells have been studied by various laboratories using media containing stress-inducing components such as Congo red, salt, calcofluor white, sodium dodecyl sulfate, caffeine, and hydrogen peroxide (16–18), but these types of cell integrity-challenging phenotypic assays have not been widely explored for *Rhodotorula* strains.

*Rhodotorula* cells have been reported to exhibit a thin layer of capsule (11). While the capsule of *C. neoformans* has been the focus of many studies, including those performed with India ink and fluorophore-tagged anticapsule antibodies, very little is known about the surface or capsule of *Rhodotorula* species. To date, there has been one report of binding of concanavalin A to environmental *Rhodotorula* strains (*Rhodosporidium toruloides*) (14); no other studies of surface-binding probes, reports of capsule-binding antibodies, or India ink images of capsule have been published for *Rhodotorula* strains.

For this study, we were interested in whether or not *R. mucilaginosa* strains isolated from patients and the environment had particular phenotypic profiles and how these strains differed from those of *C. neoformans*. Only one study to date compared various species of environmental and clinical *Rhodotorula* strains (10), and the focus was on biofilm formation. Comparisons between *Rhodotorula* and *Cryptococcus* species appear only in passing in the literature. For the purpose of this work, we focused on cell wall integrity studies, the production of virulence factors of melanization and urease, antifungal disk diffusion susceptibility, capsule characterization, and cell surface analysis by fluorescent probes to expand our understanding of *R. mucilaginosa* variability and to compare this emerging pathogen to the well-studied species *C. neoformans*.

**RESULTS**

Only strains that were genotyped as *R. mucilaginosa* were selected for the study. All putative *Rhodotorula* strains of interest yielded a DNA amplification product in the expected range of 500 bp using ITS1 and ITS4 primers and were successfully subcloned into TOPO TA vectors. These clones were successfully sequenced, trace data were assembled, and the regions were compared to database sequences. This allowed us to select and proceed with only those strains that matched *R. mucilaginosa* for further comparative analysis (see Table 1) (Fig. 1), including all eight of our clinical strains and a subset of our environmental strains.
R. mucilaginosa strains were less tolerant than C. neoformans strains to Congo red and more tolerant to caffeine on YPD plate media. We employed serial dilution plating of our R. mucilaginosa and C. neoformans strains under various cell wall integrity conditions to access their behavior. All of our strains grew well at 25 and 37°C on plain yeast extract-peptone-dextrose (YPD) agar media, although growth of strain ARY 206 (Amy Reese yeast [ARY] collection) appeared to be slightly less robust on YPD agar alone at 37°C in the shown trial than in some of our previous tests, where it grew in a manner that showed greater similarity to the growth seen with other strains. We therefore concluded that the growth changes seen on various media were related to the change in conditions and not to changes in temperature (Fig. 2).

Calcofluor white (CFW; also referred to as fluorescent brightener) disrupts the normal assembly of chitin microfibrils in the cell wall (17, 19). R. mucilaginosa strains plated on YPD media containing 1 mg/ml CFW were similar to the tested C. neoformans strains in growth characteristics (Fig. 2). Our data suggest a similar lack of impact of CFW on chitin formation in the cell walls in comparisons between the two fungi.

Congo red has been demonstrated to bind to fungal cell wall beta-D-glucans (20, 21) and/or to chitin (19, 21), interfering with cell wall construction. While the cryptococcal strains all grew robustly with 1 mg/ml Congo red in the YPD agar media at both 25 and 37°C, Rhodotorula strains were more profoundly inhibited, especially at 37°C (Fig. 2). Only two of the environmental strains showed any notable growth, while three of the clinical strains showed notable growth at 37°C. This suggests differences in the cell wall polymers of R. mucilaginosa strains in comparison to C. neoformans strains, likely in the cell wall beta-D-glucans and/or chitin composition or their assembly.

Sodium dodecyl sulfate (SDS) interrupts cell membranes and may cause cells with less-robust membranes to lyse (16, 22). The cryptococcal strains grew to the same order of magnitude in YPD agar with 0.01% SDS at both 25 and 37°C, with the notable exception being the JEC 21 strain, which failed to thrive (and which is a different serotype). The same was true for R. mucilaginosa, except for the purchased ARY 200 R. mucilaginosa strain, which did not grow at all at 37°C (Fig. 2). ARY 115, 116, 250, 201,

### Table 1: Cryptococcus and Rhodotorula strains utilized throughout experimental methods

| ARY strain | Sample origin | Sample category |
|------------|---------------|----------------|
| Cryptococcus |               |               |
| 177 | NIH 117 | Control, clinical |
| 178 | NIH 192 | Control, clinical |
| 179 | NIH 430 | Control, clinical |
| 180 | NIH 433 | Control, clinical |
| 101 | H99, clinical strain (var. grubii, serotype A) | Control, clinical |
| 105 | JEC21, clinical strain (var. neoformans, serotype D) | Control, clinical |
| Rhodotorula |               |               |
| 115 | St. Louis, MO; Washington University; laboratory contaminant; 2002 | Environmental |
| 116 | Allentown, PA; Cedar Crest College; campus isolate; 2004 | Environmental |
| 120 | Allentown, PA; Cedar Crest College; laboratory contaminant | Environmental |
| 126 | Allentown, PA; Grace Montessori School | Environmental |
| 162 | Cumberland, PA; avian dropping swab | Environmental |
| 200 | Ward’s no. 470179-708 plate or Carolina no. 156260 slant; listed as R. rubra | Environmental (purchased) |
| 201 | UICCOM; blood sample from Madrid, Spain; 2001 | Clinical |
| 202 | UICCOM; blood sample from Johannesburg, South Africa; 2008 | Clinical |
| 203 | UICCOM; blood sample from Hershey, PA; 2007 | Clinical |
| 204 | UICCOM; blood sample from Johannesburg, South Africa; 2004 | Clinical |
| 205 | UICCOM; blood sample from Szeged, Hungary; 2007 | Clinical |
| 206 | UICCOM; blood sample from Bratislava, Slovakia; 2001 | Clinical |
| 207 | UICCOM; blood sample from Edmonton, Canada; 2003 | Clinical |
| 208 | UICCOM; blood sample from Johannesburg, South Africa; 2007 | Clinical |
| 225 | Allentown, PA; Cedar Crest College; tree sample | Environmental |
| 250 | Amberson, PA; golden retriever dog coat sample | Environmental |

*a* The number indicates strains from the Amy Reese yeast (ARY) collection. The purchased strain is described as R. rubra but is cross-listed with ATCC 9449, NRRL Y-1592, and MUCL 30397, which are listed as R. mucilaginosa (Jorgensen) F.C. Harrison (1928). Strains from blood samples were obtained from the University of Iowa Carver College of Medicine (UICCOM) (1).
and 205 did not exhibit growth to the same order of magnitude at 37°C (Fig. 2b). We tested all strains on media with 0.01% SDS because the *R. mucilaginosa* strains exhibited zero growth at either temperature when we initially tested media with 0.05% SDS. This result led us to believe that the characteristics of membrane construction, stability, or accessibility in *R. mucilaginosa* strains may be different, as the rhodotorular cells were more susceptible to perturbations.

As a purine analog, caffeine can interfere with signal transduction pathways involved in cell wall production (23). The results seen with YPD agar with 1.5 mg/ml caffeine plating (Fig. 2) suggest that *R. mucilaginosa* strains are more robust in their growth than *C. neoformans* in the presence of this level of caffeine. Lighter growth of the cryptococcal strains has also been observed in the published spot-plating images for *C. neoformans* strains on 1 mg/ml caffeine (24). All of the *R. mucilaginosa* strains, both environmental and clinical, grew more robustly than cryptococcal strains at both 25 and 37°C (Fig. 2). This suggests differences in the signal transduction pathways between the two fungi and that *R. mucilaginosa* cells are compensating in cell structure integrity.

Sodium chloride has been utilized in plate media to test fungal cell wall osmotic stability (17, 19, 24). Hydrogen peroxide addition to media has been used to evaluate cell tolerance of oxidative stress (25, 26). YPD agar plates containing either 1.2 M NaCl or H₂O₂ did not appear to impact *R. mucilaginosa* cells differently from *C. neoformans* strains.
The two fungal species seem equally tolerant to osmotic and oxidative stresses under these conditions.

Environmental and clinical *R. mucilaginosa* strains produce urease. Production of urease is a virulence factor in *C. neoformans* (27). We were interested in determining whether all of the clinical and environmental strains would demonstrate production of urease and whether the strains would hydrolyze urea at similar rates. All 16 *R. mucilaginosa* strains and both tested *C. neoformans* strains, H99 and NIH 117, were positive for urease production in urea broth after 7 days at 37°C, while uninoculated media did not change color. 

![Characterization of Sixteen R. mucilaginosa Strains](msphere.asm.org)

**FIG 2** *R. mucilaginosa* strains have cell wall polymer compositions that differ from those of *C. neoformans* strains and do not exhibit melanization. Serial dilutions of six strains of *C. neoformans* (NIH 117 to 433 [as indicated], H99, and JEC21), eight environmental strains of *R. mucilaginosa*, var. *neoformans* (ARY 115 to 250 [as indicated]), and eight clinical strains of *R. mucilaginosa* (ARY 201 to 208 [as indicated]) were spotted onto YPD agar media containing cell envelope integrity-challenging ingredients or on minimal media with L-DOPA as indicated. The initial spot was 1 × 10^6 cells/ml, and subsequent spots were 5-fold dilutions. *R. mucilaginosa* strains were more susceptible to 1 mg/ml Congo red and 0.01% SDS than *C. neoformans* cells but were more robust in the presence of 1.5 mg/ml caffeine in YPD agar media. *R. mucilaginosa* strains did not melaninize.

(Top) Plates were incubated at 25°C for 4 days. (Bottom) Plates were incubated at 37°C for 4 days.

cells (Fig. 2). The two fungal species seem equally tolerant to osmotic and oxidative stresses under these conditions.
(P = 0.19 by Student’s t test) number of the environmental R. mucilaginosa strains turned pink in the first few days (average of 3.5 days) than of the clinical strains (average of 4.5 days) or the C. neoformans strains (average of 5 days).

**R. mucilaginosa strains do not produce melanin.** The activity of laccase in producing melanin from substrates plays a role in cryptococcal virulence (28). Medium containing minimal glucose and L-3,4-dihydroxyphenylalanine (L-DOPA) has been demonstrated to induce the production of melanin in cells able to perform melanization (18). This process can be visualized by observing a blackening of the cells grown on the plate. The results seen with the 1 mM L-DOPA plates (Fig. 2) demonstrated consistent and pronounced melanization at 25 and 37°C in three C. neoformans strains (NIH 117, NIH 192, and H99), while no impact on any of the 16 R. mucilaginosa strains was seen at either 25 or 37°C.

**R. mucilaginosa strains are less susceptible to fluconazole and voriconazole than C. neoformans strains.** Clinical strains of R. mucilaginosa have been analyzed for their susceptibility to disks of fluconazole and voriconazole (1), and we were motivated by curiosity to employ the same methods for comparisons of our environmental strains to the clinical strains. The clinical strains were likely investigated as a part of a study reported previously by Pfaller et al. (1), but we did not have those data for our strains of interest, so we evaluated them in this study, comparing them to our environmental strains and four cryptococcal controls. Zones were photographed and measured from plates incubated at 37°C for 2 days. C. neoformans zones of inhibition for all four strains tested showed susceptibility to voriconazole (i.e., the zones were 17 mm in diameter) (1). Two of the C. neoformans strains were susceptible (S) to fluconazole, and two were susceptible in a dose-dependent manner (susceptible dose dependent [SDD]) (S = 19 mm in diameter, SDD = 15 to 18 mm) (1) (Table 2). None of the R. mucilaginosa strains yielded any zones of inhibition in response to fluconazole. Environmental R. mucilaginosa strains 120 and 162 produced zones of inhibition in response to voriconazole (measured at 10 mm each in diameter), but since the zones were less than 14 mm in diameter, they therefore would be considered to represent resistance (1). Clinical R. mucilaginosa strains 202 and 204 showed zones of inhibition that were 23 mm and 29 mm in diameter, indicating that both were susceptible to voriconazole (Table 2).

**R. mucilaginosa strains do not make capsules as large as those made by C. neoformans strains under standard conditions.** Capsule induction is often studied in C. neoformans by placing cells under starvation conditions and imaging the results with India ink; however, R. mucilaginosa strains have not been studied this way. We chose to observe cells in phosphate-buffered saline (PBS), Dulbecco’s modified Eagle’s medium (DMEM), Sabouraud medium, and diluted (10%) Sabouraud broth under conditions maintained with and without the addition of fetal calf serum (FCS) and with and without the addition of CO₂ (29, 30). For initial condition testing, we used C. neoformans H99 for comparisons with one clinical R. mucilaginosa strain (strain 201) and one environmental strain (strain 115) (Table 3; see also Fig. 3) (Fig. 4). In binning under each of the four medium conditions (regardless of the presence or absence of FCS or CO₂), the R. mucilaginosa strains exhibited larger capsule ratios in Sabouraud media than the C. neoformans strains, but we observed the opposite result under each of the three medium conditions (Table 3). None of tested conditions caused either R. mucilaginosa strain to produce capsules to the extent seen with strain H99 (Fig. 3). Under every set of conditions, the clinical 201 R. mucilaginosa strains produced larger capsules than the environmental 115 strain (Fig. 4). We noted some changes in cell size under some of these conditions, such as enlarged cells in DMEM for both tested R. mucilaginosa strains and even some elongated germ-tube-like structures for clinical strain 201 under DMEM- and Sabouraud-containing conditions. R. mucilaginosa cells often appeared to be more closely clumped together than C. neoformans, and this is quite visible in the India ink images (Fig. 3).

A Rhodotorula-specific anticapsular antibody was generated that bound all R. mucilaginosa strains. We wanted to study the capsule and cell surface of the R.
TABLE 2 Two clinical *R. mucilaginosa* strains were susceptible to voriconazole, while no environmental strains were susceptible to voriconazole and all *R. mucilaginosa* strains were resistant to fluconazole.

| Strain          | Zone of inhibition (mm), susceptibility rating | Voriconazole | Fluconazole |
|-----------------|---------------------------------------------|--------------|-------------|
| Cryptococcus    |                                             |              |             |
| H99             | 28, S                                       | 18, SDD      |
| NIH 117         | 29, S                                       | 20, S        |
| NIH 192         | 34, S                                       | 18, SDD      |
| NIH 430         | 37, S                                       | 32, S        |
| Rhodotorula, environmental |                          |              |             |
| ARY 115         | 0, R                                        | 0, R         |
| ARY 116         | 0, R                                        | 0, R         |
| ARY 120         | 10, R                                       | 0, R         |
| ARY 126         | 0, R                                        | 0, R         |
| ARY 162         | 10, R                                       | 0, R         |
| ARY 200         | 0, R                                        | 0, R         |
| ARY 225         | 0, R                                        | 0, R         |
| ARY 250         | 0, R                                        | 0, R         |
| Rhodotorula, clinical |                          |              |             |
| ARY 201         | 0, R                                        | 0, R         |
| ARY 202         | 23, S                                       | 0, R         |
| ARY 203         | 0, R                                        | 0, R         |
| ARY 204         | 29, S                                       | 0, R         |
| ARY 205         | 0, R                                        | 0, R         |
| ARY 206         | 0, R                                        | 0, R         |
| ARY 207         | 0, R                                        | 0, R         |
| ARY 208         | 0, R                                        | 0, R         |

"C. neoformans* (H99, NIH 117 to 430 as indicated), *R. mucilaginosa* environmental (ARY 115 to 250 as indicated), and *R. mucilaginosa* clinical (ARY 201 to 208 as indicated) strains were grown in YPD medium overnight at 30°C, and equivalent cell amounts were plated onto Mueller-Hinton plates. Two disks for each antifungal agent were placed onto each plate, and the plates were incubated for 2 days at 37°C before imaging and measuring. Zone-of-inhibition measurements (in millimeters) are listed followed by the susceptibility rating of susceptible (S), susceptible dose dependent (SDD), or resistant (R) as defined previously by Pfaller et al. (1). All of the *C. neoformans* strains were susceptible to voriconazole (zone of inhibition, over 17 mm [1]). Two environmental *R. mucilaginosa* exhibited zones of inhibition in response to voriconazole, but with zones of inhibition of less than 14 mm, they are considered resistant (1). Two clinical *R. mucilaginosa* strains were susceptible to voriconazole. Two of the *C. neoformans* strains were susceptible to fluconazole, and two were susceptible dose dependent (S = 19 mm; SDD = 15 to 18 mm [1]). None of the *R. mucilaginosa* strains yielded any zones of inhibition in response to fluconazole.

TABLE 3 *R. mucilaginosa* strains have larger capsule ratios than *C. neoformans* strains in Sabouraud media.

| Medium | $V_{cell}/V_{cell}$ | $P$ value |
|--------|---------------------|-----------|
|        | H99 (n)             | R115 (n)  | R201 (n)  | H99/R115  | H99/R201  | R115/R201 |
| PBS    | 4.5 ± 1.6 (121)     | 3.2 ± 1.0 (221) | 3.4 ± 1.7 (64) | <0.0001  | <0.0001  | 0.3286     |
| DMEM   | 5.1 ± 3.6 (92)      | 2.6 ± 1.0 (150) | 3.0 ± 1.1 (168) | <0.0001  | <0.0001  | 0.0025     |
| Sab    | 2.2 ± 0.4 (154)     | 3.1 ± 0.9 (185) | 3.4 ± 1.2 (339) | <0.0001  | <0.0001  | 0.0003     |
| TEN    | 6.7 ± 8.4 (92)      | 3.1 ± 0.9 (150) | 3.7 ± 1.4 (168) | <0.0001  | <0.0001  | <0.0001    |

"Capsule induction was measured for H99 *C. neoformans*, ARY 115 environmental *R. mucilaginosa*, and ARY 201 clinical *R. mucilaginosa* under conditions of exposure to phosphate-buffered saline (PBS), Dulbecco’s modified Eagle’s medium (DMEM), Sabouraud (Sab) medium, or 10% diluted Sabouraud media (TEN). Data represent average capsule ratio ± standard deviation of total cell volume with capsule ($V_{cell}$) to cell volume without capsule ($V_{cell}$) of the different strains under the four different medium conditions tested (each medium condition was also examined with or without CO2 and with or without 10% FCS, but those data have been collapsed for this analysis). n, number of cells analyzed; P value, result from unpaired Welch’s two-sample t test as implemented in R. By this analysis, *C. neoformans* strain H99 had a larger capsule ratio value in PBS, DMEM, and 10% diluted Sabouraud media; however, *R. mucilaginosa* had a larger capsule ratio value in normal Sabouraud media.
**FIG 3** *R. mucilaginosa* strains do not produce capsules as large as those of *C. neoformans* under standard capsule-inducing conditions. Sixteen growth conditions are shown for the following three example strains: H99 *C. neoformans*, ARY 115 environmental *R. mucilaginosa*, and ARY 201 clinical *R. mucilaginosa*. Equivalent numbers of cells were introduced to wells containing PBS, DMEM, Sabouraud (Sab), or 10% diluted Sabouraud media (as indicated), with or without CO2 and with or without 10% FCS, and incubated for 1 week at 37°C. The experiments performed under the indicated CO2 conditions were performed at the same time for all strains. Samples of each well were mixed with India ink and visualized. While the DMEM and 10% Sabouraud conditions appeared to produce the largest capsules for H99, the *R. mucilaginosa* capsules were not nearly as large under any of the conditions. Bar, 10 µM. All images were taken at the same resolution and prepared in the same manner.
fluorescent rings around *Rhodotorula* cells and that antibody binding was specific to *Rhodotorula* species (Fig. 5A) and also observed that the antibody did not bind to cryptococcal cells (Fig. 5B). We have named this *Rhodotorula*-specific antibody Rh1. Furthermore, we observed that the *Cryptococcus* anticapsular antibody bound specifically to cryptococcal cells (Fig. 5C) and did not bind to rhodotorular cells (Fig. 5D).

**FIG 4** Clinical *R. mucilaginosa* strain 201 produces larger capsules than environmental *R. mucilaginosa* strain 115. The same experiments were performed as described for Fig. 3 for the following strains: H99 *C. neoformans*, ARY 115 environmental *R. mucilaginosa*, and ARY 201 clinical *R. mucilaginosa*. After incubation of equivalent numbers of cells in PBS, DMEM, Sabouraud, or 10% diluted Sabouraud media, with or without CO2 and with or without 10% FCS (as described in Materials and Methods and the Fig. 3 legend), samples were mixed with India ink. Four to eight pictures were taken for each of the 16 conditions for each of the three strains to capture random and representative images. The diameters of the cell and capsule and the cell alone without capsule were measured in ImageJ for as many cells as could be clearly determined in each image. The ratios of cell volume with capsule (\(V_{\text{Tot}}\)) and cell volume without capsule (\(V_{\text{cell}}\)) are shown in gray dots. The bottom and top edges of the box plot correspond to the first and third quartiles of the data, respectively, with the vertical lines corresponding to no greater than 1.5 \(\times\) the interquartile range. The middle line of each box represents the median of the data. Each condition was well represented by multiple measurements, with the exception of strain 201 in PBS, in which too few cells were noted with measureable contrast.
All tested Rhodotorula strains bound the Rh1 anti-capsule antibody, whereas C. neoformans strains did not. Samples of each of the 16 R. mucilaginosa strains were incubated with the purified primary anti-Rhodotorula anti-capsule antibody (Rh1) followed by the goat anti-rabbit IgG fluorescein isothiocyanate (FITC) secondary antibody and visualized for the uniformity of fluorescent rings. All of the environmental and clinical strains picked up the antibody and produced intense and uniform ring fluorescence (see Table 4) similarly to the manner in which C. neoformans picks up its respective anti-capsule antibodies (31, 32). In fact, all of the Rhodotorula samples in our laboratory collection have been able to bind the Rh1 antibody, regardless of their genotyped species. We have tested nearly 50 strains.

R. mucilaginosa cells bound WGA tightly, CFW slightly less tightly, and EY considerably less tightly than and ConA about the same as C. neoformans cells. To further characterize the accessible surface, the 16 R. mucilaginosa strains and two cryptococcal control strains were each incubated with FITC-conjugated wheat germ agglutinin (WGA), calcofluor white (CFW), eosin Y dye (EY), and FITC-conjugated concanavalin A (ConA) separately and cells were then visualized with fluorescent imaging to observe surface-binding patterns.

Binding of WGA is interpreted to demonstrate exposed chitin and chitooligomers (24). All 16 R. mucilaginosa strains appeared to bind WGA more tightly than C. neoformans, as indicated by the presence of rings showing brighter fluorescence, suggesting that these components are more accessible in Rhodotorula strains, at least under these conditions (Table 4; see also Fig. 6). Calcofluor white (CFW) binds to both chitin and chitosan of the cell wall, and, because of its smaller molecular size, CFW is...
thought to indicate the total level of chitin and chitosan content (24). All of the \textit{R. mucilaginosa} strains bound CFW with high intensity, but \textit{C. neoformans} cell binding was even brighter. Our data show that \textit{R. mucilaginosa} strains bound CFW at lower levels than \textit{C. neoformans} (Table 4) (Fig. 6), suggesting that the total chitin and chitosan content in the \textit{Rhodotorula} cells may have been less than in the \textit{C. neoformans} cells. Eosin Y dye binds specifically to chitosan (17, 24). Cryptococcal cells bound the eosin Y more tightly and brightly than \textit{R. mucilaginosa}, where the fluorescent rims were much thinner if even visible (Table 4) (Fig. 6), suggesting the level of chitosan is lower in the rhodotorular walls. This result also supports the idea of the reduction of CFW binding referred to above and may support the idea that the reduction of chitosan levels accounts for the difference.

Concanavalin A (ConA) has been used to monitor mannose on fungal cell surfaces, such as on \textit{C. neoformans} cells (18, 24). All of the \textit{R. mucilaginosa} strains bound ConA with at least moderate intensity, and four environmental strains (ARY 115, 162, 225, and 250) and two clinical strains (ARY 202 and 206) bound ConA with high intensity. \textit{C. neoformans} control strains bound ConA with moderate or high intensity. The binding of ConA suggests that the accessible mannan proteins of the \textit{R. mucilaginosa} cells and \textit{C. neoformans} cells are relatively similar under these conditions.

**DISCUSSION**

We set out to characterize \textit{R. mucilaginosa} strains collected from the environment and from patients and to compare them to \textit{C. neoformans} strains in terms of their growth under cell envelope-challenging conditions, ability to undergo melanization, capsule production, susceptibility to common antifungals, and surface accessibility. We found that the strains obtained from various environmental locations or clinical spec-

---

**TABLE 4** All 16 \textit{R. mucilaginosa} strains bound in the anti-\textit{Rhodotorula} capsule antibody assay, as well as in the WGA, CFW, and ConA assays, but did not bind EY tightly*  

| ARY strain | Intensity of fluorescence |
|------------|---------------------------|
|            | Rh1 | WGA | CFW | ConA | EY  |
| \textit{Rhodotorula}, environmental |       |     |     |      |     |
| 115        | ++  | ++  | ++  | ++   | +   |
| 116        | ++  | ++  | ++  | ++   | -   |
| 120        | ++  | ++  | ++  | ++   | -   |
| 126        | ++  | ++  | ++  | ++   | +   |
| 162        | ++  | ++  | ++  | ++   | -   |
| 200        | ++  | ++  | ++  | ++   | -   |
| 225        | ++  | ++  | ++  | ++   | +   |
| 250        | ++  | ++  | ++  | ++   | -   |
| \textit{Rhodotorula}, clinical |       |     |     |      |     |
| 201        | ++  | ++  | ++  | ++   | -   |
| 202        | ++  | ++  | ++  | ++   | -   |
| 203        | ++  | ++  | ++  | ++   | -   |
| 204        | ++  | ++  | ++  | ++   | -   |
| 205        | ++  | ++  | ++  | ++   | +   |
| 206        | ++  | ++  | ++  | ++   | +   |
| 207        | ++  | ++  | ++  | ++   | +   |
| 208        | ++  | ++  | ++  | ++   | +   |
| \textit{Cryptococcus}, clinical |       |     |     |      |     |
| 101 (H99)  | -   | ++  | +++ | +++  | ++  |
| 177 (NIH 117) | -  | ++  | +++ | +++  | ++  |

*\textit{R. mucilaginosa} and \textit{C. neoformans} strains were grown in YPD media overnight at 30°C, and equivalent cell amounts were incubated with the anti-\textit{Rhodotorula} capsule antibody, Rh1, followed by the FITC-conjugated goat anti-rabbit IgG secondary antibodies as described in Materials and Methods and shown in Fig. 5. Surface probes of FITC-WGA, CFW, EY, or FITC-ConA were incubated as described in Materials and Methods and shown in Fig. 6. The intensity of fluorescence was scored, in a manner similar to what was reported previously for \textit{C. neoformans} (42), as follows: ++++, intense fluorescence (generated for \textit{C. neoformans} with CFW after viewing these cells); +++, bright fluorescence; ++, moderate fluorescence; +, low fluorescence; -, thin rim of fluorescence (seen after viewing EY-tagged cells); --, no fluorescence. Cells were randomized before being viewed, and sample sets were viewed consistently by one individual.
imens did not appear to behave uniformly phenotypically and biochemically, despite all being typed as *R. mucilaginosa*. They also behaved differently from strains of *C. neoformans*. These differences are summarized as follows.

Phenotypic and biochemical characterization of an organism provides a greater understanding of how the organism survives in different environments. Understanding the biogenesis and integrity of a cell wall and cell membrane could be useful in future antifungal production or applications. We hypothesized that the *R. mucilaginosa* strains would be susceptible to various conditions in a manner similar to that seen with *C. neoformans*, and we predicted that the clinical *R. mucilaginosa* strains would be more robust than the environmental ones. The *R. mucilaginosa* strains showed marked growth inhibition on YPD agar plates containing 1 mg/ml Congo red, whereas the cryptococcal strains were not affected. Furthermore, greater numbers of environmental strains were inhibited than clinical strains (two environmental strains exhibited at least some growth in comparison to five clinical strains; see Fig. 2). From this we conclude that there are differences between rhodotorular and cryptococcal cell wall polymer (beta-1,3-glucans or chitin) composition and/or assembly.

The literature demonstrates that wild-type cryptococcal strains (H99) grow well on media with 0.02% SDS (18), 0.05% SDS (33) and 0.06% SDS (24). We initially plated serial dilutions on YPD agar plates with 0.05% SDS, but we then dropped the concentration of SDS to 0.01% in order to view growth of *R. mucilaginosa* strains, and at that concentration, several strains grew at an order of magnitude less, suggesting that the

![FIG 6](image.png)
membranes of *R. mucilaginosa* cells are not as tolerant of surfactant interruptions as cryptococcal strains.

Our data demonstrated that *R. mucilaginosa* strains were more robust in their growth on YPD plates with 1 mg/ml caffeine than what we observed for cryptococcal growth (the literature reports for cryptococcal cells on caffeine plates [24] support what we observed). The excellent growth of both environmental and clinical *R. mucilaginosa* strains in 1 mg/ml caffeine (Fig. 2) suggests potential signaling differences between *R. mucilaginosa* and *C. neoformans*.

The production of urease enzyme and the conversion of urea to ammonia and carbamate in *C. neoformans* have been demonstrated to enhance invasion into the central nervous system (CNS) (27). *R. mucilaginosa* associated with endocarditis has been demonstrated to be positive for urease production (34). Our urease data suggest that all of the strains hydrolyze urea, than there is an inherent range in terms of hydrolysis rates across the strains, and that clinical isolation does not enhance urease reaction capacity. Whether or not the production of urease in *R. mucilaginosa* strains allows the cells better access to the CNS is unclear, but urease could theoretically facilitate the activity of *R. mucilaginosa* in cases of meningitis.

Our India ink studies (Table 3) (Fig. 3 and 4) suggested that the capsule sizes of *R. mucilaginosa* are not nearly as expansive as those of *C. neoformans*, at least under the conditions employed. This is not totally surprising. Strains of *Rhodotorula* have been described as having a small capsule (11), and *C. neoformans* has traditionally been considered the only encapsulated pathogenic fungus. Our *C. neoformans* capsule results are in line with those seen previously (29, 30), and some of the variability in our measurements of total capsule plus cell volume may have been due to the length of time of our incubation, as discussed previously by Zaragoza et al. (29). Under every set of conditions, the clinical strain 201 capsules were larger than the environmental *R. mucilaginosa* strain 115 capsules. While not necessarily correlated to strain 201 having been originally isolated from a patient, it is interesting that the clinical strain produced larger capsules. Intriguingly, capsule ratios in Sabouraud media were larger for *R. mucilaginosa* strains than for the *C. neoformans* strain, underscoring the differences in the yeast cells and the importance of testing various conditions.

The smaller capsules of *R. mucilaginosa* could contribute to greater accessibility of chitin and chitosan, which would fit with our data showing WGA binding more abundantly and brightly to *R. mucilaginosa* strains than to *C. neoformans* (Table 4). Because of its smaller molecular size, CFW is thought to indicate the total content level of chitin or chitooligomers that could be reached by the dye (24). Our data show *R. mucilaginosa* strains binding CFW less than was bound by *C. neoformans* (Table 4), suggesting that the total content of chitin or chitooligomers in *R. mucilaginosa* cells may be less than in *C. neoformans* cells. This is further supported by our EY binding data (Table 4) demonstrating low binding levels and low levels of chitosan in *R. mucilaginosa* cells. In conclusion, we take these findings to suggest that the amounts of chitin and, particularly, of chitosan are lower in *R. mucilaginosa* cells but that these components are more accessible than in *C. neoformans*.

All of the *R. mucilaginosa* strains were resistant to fluconazole. Only two of the clinical strains (ARY 202 and 204) were susceptible to voriconazole, while all of the environmental *R. mucilaginosa* strains were resistant to voriconazole (Table 2). In contrast, all four of the tested *C. neoformans* strains were susceptible to voriconazole, and all four were either susceptible or susceptible in a dose-dependent manner (1) to fluconazole. These results are in line with what has been published previously for the same method, where the majority of isolates of *R. mucilaginosa* strains were resistant to fluconazole, there was a range of responses to voriconazole, and *C. neoformans* strains were generally susceptible to voriconazole and fluconazole (1). We also note that just because our environmental strains were isolated from environmental sites does not mean that they could not cause clinical infections. But our data suggest that if they did, they would not respond to these antifungal agents. We did not see any specific
correlation between the two voriconazole-susceptible clinical strains and their growth on cell wall integrity plates that we could link with the antifungal results.

Our capsule analysis studies performed using an antibody to the *R. mucilaginosa* capsule demonstrated the potential value of the use of such a tag to identify and study putative *Rhodotorula* cells collected from both clinical and environmental settings (Table 4) (Fig. 5). Currently, a major clinical challenge in treating infections caused by *Rhodotorula* spp. is that of not expecting its presence. Given that *Rhodotorula* strains do not respond to the first-line antifungal caspofungin, this delay in identification can have serious consequences. Susceptibility tests have demonstrated that *Rhodotorula* species respond best to amphotericin B and flucytosine and very poorly to the azoles (1, 7–10). Our data corroborate this lack of efficacy of azoles for control of environmental strains as well. Availability of a specific antibody could be useful in rapid diagnostic approaches for detection of infections caused by *Rhodotorula* spp. To our knowledge, this is the first work that has studied the capsule of *R. mucilaginosa* with any anti-capsule antibodies or with a focus on the capsule of this fungal pathogen.

Taken together, the cell envelope integrity, capsule analysis, and fluorescent-probe binding results presented here suggest that the pathways and composition of *R. mucilaginosa* cell walls and capsules are different from those of cryptococcal cells. *R. mucilaginosa* appears to have less chitin and chitosan, though these cell wall components may be more accessible than in *C. neoformans*, perhaps because of the presence of thinner capsules. The marked reduction of *R. mucilaginosa* levels on Congo red media may suggest an impact on the production or assembly of glucan or chitin levels in these cells. The robust growth of *R. mucilaginosa* on caffeine-containing plates supports the idea that the signaling pathways of these cells differ from those of *C. neoformans* regarding cell wall stability and repair. The *R. mucilaginosa* strains from clinical sources exhibited a slightly higher tolerance of cell wall integrity challenges and larger capsules than were shown by strains from environmental sources, and the environmental strains exhibited higher levels of resistance to antifungal agents. This work suggested that future studies that dig deeper into the cell wall and capsule composition of *Rhodotorula* spp. could prove fruitful and might inform the efficacy of future antifungal treatments or antifungal production. Our generation of the Rh1 antibody specific to *Rhodotorula* fungi could be a useful diagnostic tool, and the present report is the first known report of such a tool in the literature.

**MATERIALS AND METHODS**

**Strains and strain maintenance.** Eight clinical *R. mucilaginosa* strains isolated from blood were obtained from the Medical Microbiology Division at the University of Iowa Carver College of Medicine, Iowa City, IA, as listed in Table 1. Environmental *Rhodotorula* strains were collected by various members of the Reese laboratory from locations in St. Louis, MO, or from locations in Allentown, PA, or from other locations in Pennsylvania or were purchased as a control strain from Wards or Carolina (Table 1). Clinical *Cryptococcus neoformans* strains (var. *grubii* serotype A H99 and var. *neoformans* serotype D JEC21) were obtained from Tamara L. Doering (Washington University School of Medicine, St. Louis, MO) and the NIH strains from Arturo Casadevall (Johns Hopkins University). Strains were stored at −80°C in yeast extract-peptone-dextrose (YPD) media with 15% glycerol until utilized and were cultured on YPD agar plates at 30°C for study.

**Isolation of genomic DNA.** Genomic DNA (gDNA) was extracted using a Zymo fungal/bacterial DNA extraction kit (Zymo catalog no. D6005), and approximately 100 μg of each strain was scraped from growth on a YPD agar petri dish. Kit protocols were followed, save for the bead beater time being reduced to two separate 2-min intervals, for a total of 4 min per sample, to avoid overheating of tubes. Yields of gDNA ranged from 5 ng/ml to 30 ng/ml as determined by the use of NanoDrop ND-1000 spectrophotometer (NanoDrop) readings. Alternatively, for some strains, gDNA was extracted from overnight YPD liquid cultures with a PowerSoil DNA isolation kit (Mo Bio Laboratories), according to the manufacturer’s protocol, and was quantified by Qubit 3 Fluorometer (Invitrogen) readings.

**Amplification of internal transcribed spacer (ITS) regions.** ITS regions were amplified using standard fungal methods (35) with either Qiagen Taq PCR master mix (Qiagen, catalog no. 201443) or REDTaq ReadyMix PCR mix (Sigma-Aldrich Inc., catalog no. R2523), and primers ITS1 (5’-TCCGTAAGTGA ACCTGCGG-3’) and ITS4 (5’-TCCGCTTGATATGC-3’) (36). Amplification conditions employed were as follows: 94°C (3 to 4 min); 30 to 35 cycles of 94°C (1 min), 55°C (2 min), 72°C (1 to 2 min), and 72°C (7 min); a hold at 4°C. Amplicons were confirmed using DNA gel electrophoresis with 1% agarose gels in 1× Tris-acetate-EDTA (TAE) or 1× Tris-borate-EDTA (TBE) buffer and visualized with ethidium bromide, with the expected product being about 500 bp in size.
ITS region sequencing and analysis. Amplicons were cloned into a TOPO TA cloning kit for sequencing (Invitrogen), and duplicate Sanger sequencing reactions were performed with M13 primers at the Protein and Nucleic Acid Chemistry Laboratory at the Washington University School of Medicine. Trace data were analyzed and assembled into contigs, and all of the strains in the full set currently under study in the laboratory (about 50 strains) were genotyped via targeted-locus nucleotide BLAST (Basic Local Alignment Search Tool). Only strains that matched *R. mucilaginosa* were selected for further comparative analysis (see Table 1) (Fig. 1).

Molecular phylogenetic analysis was performed by the maximum likelihood method. The evolution-ary history was inferred by using the maximum likelihood method based on the Kimura 2-parameter model (37). The initial tree(s) for the heuristic search was obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the maximum composite likelihood (MCL) approach and then selecting the topology with the superior log likelihood value. Evolutionary analyses were conducted in MEGA7 (38). Multiple isolates of pink yeast were sequenced and analyzed, and only the strains whose best match was *R. mucilaginosa* and which formed a consistent clade with known *R. mucilaginosa* strains were used for the studies presented here.

Cell wall integrity analysis. In tests of cell wall integrity, exposure of organisms such as *Cryptococcus neoformans* and *Saccharomyces cerevisiae* to different conditions has been reported in the literature and we employed some of these here to assess the cell envelopes of our strains, including Congo red, calcofluor white, sodium dodecyl sulfate, caffeine, hydrogen peroxide, and sodium chloride (16–18, 25). Strains were grown in liquid YPD culture overnight, diluted to an optical density at 600 nm (OD<sub>600</sub>) of 0.1, serially diluted 5-fold in YPD liquid media, and spotted in 5-μl increments on two plates of YPD medium alone or YPD medium containing 0.05% SDS (Bio Rad Laboratory catalog no. 161-0301) or 0.5 or 1.0 mg/ml calcofluor white (Fluorescent Brightener 28; Sigma catalog no. F-3543) prepared from a stock solution pH 11: 1.5 mg/ml caffeine (Sigma catalog no. C-0750); 0.5% Congo red (Fisher Laboratory Chemical catalog no. A-795) prepared from a stock solution with 50% ethanol; 1.2 M NaCl (Research Products International Corp. catalog no. S23020); or 1 mM hydrogen peroxide (Walgreens) (3%). Two replicate plates corresponding to each condition were incubated at 37°C for 3 days, and at 25°C for 7 days. Before the plates were scanned with an Epson color scanner, images were captured with VueScan ×64 software, and Photoshop CS4 was used to prepare figures.

Urease production assay. Three separate 2-ml aliquots of urease media (Remel) were inoculated with 2.5 × 10<sup>7</sup> cells of each strain and incubated at 37°C for 7 days. Samples were viewed on a nearly daily basis to determine which samples hydrolyzed urea more quickly than others and were categorized for any change in the color of the medium, with a change from light pink to hot pink indicating a positive reaction for the hydrolysis of urea. All 16 *R. mucilaginosa* strains were tested and compared to C. neoformans strains H99 and NIH 117.

Melanin production assay. Strains were grown in liquid YPD culture overnight, diluted to an OD<sub>600</sub> of 0.1, serially diluted 5-fold in YPD liquid media, and spotted in 5-μl increments onto plates of minimal medium (10 mM MgSO<sub>4</sub>, 29.4 mM KH<sub>2</sub>PO<sub>4</sub>, 13 mM glycine, and 3 mM thiamine, pH 5.5) supplemented with 1.5 mM glucose and 1 mM L-DOPA, modified from the composition previously reported by Eisenman et al. (39) to have more dextrose.

Antifungal susceptibility. Strains were grown in liquid YPD culture overnight and diluted to an OD<sub>600</sub> of 0.1, 1 ml was spread across 150-mm-diameter Mueller-Hinton plates (Remel lot 289991) with a sterile swab, and the plates were rotated 90° and spread further and finally rotated 90° and swabbed again for thorough spreading. Sterile tweezers were used to apply two antifungal disks of fluconazole and two of voriconazole to each sample. Plates were incubated at 37°C for 2 days, scanned, and measured.

India ink capsule visualization. Strains were grown in liquid YPD culture overnight, and the concentrations were determined at OD<sub>600</sub> via a spectrophotometer (OD<sub>600</sub> of 1 = 1 × 10<sup>7</sup> cells). Aliquots of 5 × 10<sup>7</sup> cells per well were washed in the appropriate growth condition (all samples maintained under the same conditions were washed in bulk) and resuspended in the same growth media and added to the wells in 100-μl volumes. In cases in which fetal calf serum was a part of the condition, the fetal bovine serum (Sigma F2442) was added in 200-μl aliquots to reach 10% of the final concentration. Medium conditions included phosphate-buffered saline (PBS), DMEM (with 4.5 g/liter d-glucose and L-glutamine and 110 mg/liter sodium pyruvate [Gibco 11995-065]), Sabouraud (BD 238230), and Sabouraud diluted to 10% to reach a final volume of 2 ml per well. Plates for CO<sub>2</sub> conditions were placed in a plastic bag all at one time, CO<sub>2</sub> was added to the bag, and the bag and contents were incubated at 37°C for 7 days. A dot of India ink (Hardy Diagnostics Z64) and a loopful of the well samples were transferred to slides and mixed for visualizing capsules. The cells were viewed with a Zeiss Scope A.1 microscope at ×630, images were captured with an AmScope 5.2-megapixel (MP) camera, and Photoshop CS4 was used to prepare figures.

For each of the three strains and 16 conditions, four images were captured in a general diagonal pattern across the slide, with photographing of up to four additional images around the slide performed if insufficient cells were observed in the original set of four samples. Images were batch processed in the Fiji distribution of ImageJ (40) in order to standardize measurement of the cell diameters. Each image was converted to 8-bit type, and the threshold value was set to 221 to create a black India ink background with distinct capsule borders. For each cell, the diameter of the cell capsule and the diameter of the cell membrane were measured in ImageJ and converted to a volume value using the equation 4/3 × π × (diameter/2)<sup>2</sup> × volume. The ratio reported is the total cell volume (V<sub>cell</sub>) divided by the cell volume without capsule (V<sub>cap</sub>). These methods are comparable to those used to calculate capsule volumes for *C. neoformans* in the literature (29, 30).
Preparation of capsule material for antibody production. *R. mucilaginosa* strain ARY 115 conditioned media were generated by culturing cells inoculated from a actively growing plate into 25 ml minimal media (BD Difco yeast nitrogen base without amino acids; catalog no. DF0919) for 4 to 5 days at 30°C with shaking (New Brunswick Scientific Co.; Innova 4000 table top shaken) at around 225 rpm. This strain was selected as it was the original *Rhodotorula* strain in the Reese laboratory and had been treated as a reference strain. The cells were pelleted at low speed (Beckman Coulter Allegra 25R centrifuge), and the supernatant was subjected to sterile filtration and buffer exchange into phosphate-buffered saline (PBS; pH 7.4) (Centricon centrifugal filter device kit by Millipore) in order to obtain the shed capsule material without extraneous medium components. A phenol sulfuric acid assay was used to determine the concentration of carbohydrate in the sample (method adapted from reference 41).

Generation of rabbit sera against *Rhodotorula* capsule. Samples of capsule determined to contain 0.2 mg carbohydrate were sent to Lampire Biological Laboratories (Pipersville, PA) for inoculation into two separate rabbits. Serum samples were obtained from each rabbit for control experiments and possible antibody synthesis at the following time points: before the injection, 30 days postinjection, 50 days postinjection, and at the final termination bleeds.

Testing of rabbit antisera for binding to *Rhodotorula* capsule. Overnight cultures of both *R. mucilaginosa* strain ARY 115 and *C. neoformans* strains JEC21 and H99 were prepared. The cells were counted with a hemocytometer or measured by spectrophotometer, and aliquots of 2.5 × 10⁶ cells/μl were centrifuged for 1 min at high speed on a tabletop minicentrifuge (e.g., at 14,000 rpm with the Eppendorf 5415D Microcentrifuge) and were washed once with 1 ml of PBS for each of the testing conditions. Samples were resuspended in 250 μl of 1% bovine serum albumin (BSA)–1% PBS (to decrease nonspecific binding), and 25 μl of a 1:1 antiserum dilution (100 μl for PBS to control for the absence of antibody) was added and incubated at room temperature with rotation for 30 min as the primary antibody incubation step. Cells were centrifuged and washed in 1 ml of PBS to remove excess primary antibody. Cells were resuspended in 49 to 250 μl of 1% BSA–1% PBS and incubated with anti-rabbit IgG conjugated to fluorescein isothiocyanate (FITC) from goat (Alfa Aesar BT 557; catalog no. J64967) as a secondary antibody to reach final concentrations of 1 to 10 μg/ml and rotated at room temperature for 30 min. *C. neoformans* controls using antcapsular antibody directly conjugated with a fluorophore, such as 3C2-Cy3, were also used to serve as fluorescence controls (requiring alternative filters) as previously described (31). Cells were viewed using fluorescence microscopy.

Purification of the *Rhodotorula* antibody and strain analysis. The terminal bleed rabbit sera from rabbit 1 were purified using a protein A IgG purification kit (Thermo Scientific). The eight clinical and eight environmental strains were incubated with the primary and secondary antibodies as described above and assessed for binding of the anti-*Rhodotorula* anticapsular antibody.

Immunofluorescence visualizing and imaging. The cells were viewed with a Zeiss Scope A.1 microscope at ×630, images were captured with an AxioScope 5.2-MP camera using appropriate excitation cubes, and Photoshop CS4 was used to prepare figures. If an uninterrupted and uniform fluorescent ring was visible surrounding the cell, this was interpreted as indicating that the primary and secondary antibodies attached to the cell were present as described previously (32).

Surface characterization of *Rhodotorula* cells. The 16 *R. mucilaginosa* strains were screened for their ability to bind the primary antibody (Rh1) and secondary antibodies for the capsule (as described above). To probe the accessible surface of the different strains (in a manner similar to that performed with *C. neoformans* strains as described by Reese and Doering [31]), aliquots of 2.5 × 10⁶ cells/μl to 2.5 × 10⁷ cells/μl grown in YPD media were incubated with FITC-wheat germ agglutinin (Invitrogen catalog no. W834) at final concentrations of 0.1 to 0.5 mg/ml in 1% BSA or with FITC-concanavalin A (Molecular Probes) at final concentrations of 0.1 to 0.4 mg/ml in 1% BSA for 60 min at room temperature. Samples tagged with eosin Y dye (final concentration of 250 μg/ml) were washed and resuspended in McVainue’s buffer (0.2 M Na₂HPO₄, 0.1 M citric acid, pH 6.0) and incubated for 15 min at room temperature. Cell aliquots were also incubated with up to 1 ampule of calcofluor white (BD BBL diagnostic stain reagent; catalog no. 261195) for 30 min with rotating at room temperature. In each case, samples were incubated and washed in PBS before viewing. Samples were generally randomized before assessment for fluorescence visualization as described above, and all samples tagged with the same probe were viewed by the same individual.

ACKNOWLEDGMENTS

*Rhodotorula* clinical strains were generously provided by Michael Pfaller and his staff. Clinical *Cryptococcus neoformans* strains were generously provided by Tamara L. Doering or Arturo Casadevall. Environmental *Rhodotorula* strains (Table 1) were collected by Jessica Reed, Sarah Williams, Rachel Dutko Trecki, and Jessica Hile. The 3C2 and 2H1 cryptococcal antibodies were generously provided by Thomas Kozel and Arturo Casadevall, respectively. An eosin Y dye aliquot was a gift from the Doering laboratory. Urea and Mueller-Hinton media were provided by Kamelia Markova and the St. Louis College of Pharmacy (STLCOP) microbiology laboratory. Preliminary data collection and interpretation were carried out by Natalie Akers (NA), Alex Metzger, Carrie Olson (C.O.), Catherine Beecher (C.B.), Alicia Dyson, Jessica Reed, Jeanette Stadnik, Lauren McKeen, Jennifer Simmons, and Maria Zhang. Alonzo Pierre, Joel Arackal, and Sreemathi Palanisamy assisted briefly with data collection. Kami Hancock reviewed
the manuscript, Andrew Alspaugh’s laboratory provided medium guidance, and Tamara L. Doering and Jennifer Lodge provided feedback on the data.

Undergraduate research funding awards of up to $500 were provided by the Pennsylvania Academy of Sciences to C.O. to generate anti-Rhodotorula capsule antibodies, to C.B. for Rhodotorula capsule binding analysis, and to N.A. for genotypic analysis. Two Faculty Research Incentive Funds grants from the STLCOP Research and Scholarly Activity Committee to A.J.R. and one to both A.J.R. and J.J.O. and startup monies from STLCOP (A.J.R.) were used to fund this work.

REFERENCES

1. Pfaffer MA, Diekema DJ, Gibbs DL, Newell VA, Bjije H, Dzierzanowska D, Klimko NN, Letscher-Bru V, Lisalova M, Muehlthaler K, Rennison C, Zaidi M, Global Antifungal Surveillance Group. 2009. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole. Antimicrob Agents Chemother 53:4521–4525. https://doi.org/10.1128/AAC.00178-09

2. Baradkar VP, Kumar S. 2008. Meningitis caused by Cryptococcus neoformans. J Clin Microbiol 46:1710–1719. https://doi.org/10.1128/JCM.01747-08

3. Tisdas R, Papaageorgiou S, Melotisadis J, Tofas P, Sappa V, Panayiotides J, Karakitsos P, Armaganidis A, Petrikos G. 2014. Rhodotorula mucilaginosas associated meningitis: a subacute entity with high mortality. Case report and review. Med Mycol Case Rep 6:46 –50. https://doi.org/10.1016/j.mcmcr.2014.08.006

4. Wirth F, Goldani LZ. 2012. Epidemiology of Rhodotorula: an emerging pathogen. Interdiscip Perspect Infect Dis 2012:465717. https://doi.org/10.1155/2012/465717

5. Tuon FF, Costa SF. 2008. Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol 25:135–140. https://doi.org/10.1016/S1131-4200(08)70052-9

6. El-Tahawy AT, Khalaf RM. 1999. Rhodotorula rubra fungemia in an immunocompromised patient. Ann Saudi Med 19:533–535. https://doi.org/10.1016/S0256-4947(99)50033-3

7. Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR. 2003. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol 41:5233–5235. https://doi.org/10.1128/JCM.41.11.5233-5235.2003

8. Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA. 2005. Activities of voriconazole determined by CLSI standardized disk diffusion testing. J Antimicrob Chemother 55:312–316. https://doi.org/10.1093/jac/dki020

9. Cox GM, Mukherjee J, Cole GT, Casadevall A, Perfect JR. 2000. Urease as a virulence factor in experimental cryptococcosis. Infect Immun 68:237–241. https://doi.org/10.1128/IAI.68.1.237-241.2000

10. Tuon FF, Costa SF. 2008. Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol 25:135–140. https://doi.org/10.1016/S1131-4200(08)70052-9

11. Cohen LS, Perfect JR, Antimicrobial Therapeutics Committee. 1999. List of antifungal drugs for reviews and publication guidelines. J Antimicrob Chemother 43:476 – 478.2005

12. Esher SK, Ost KS, Kohlbrenner MA, Pianalto KM, Telzrow CL, Campuzano A, Nichols CB, Munro C, Wormley FL, Jr, Alspaugh JA. 2018. Defects in single protein S-acyl transferase acts through diverse substrates to affect fungal cell wall remodeling and cap- 

13. Zaragoza O, Casadevall A. 2004. Experimental modulation of capsule size and antifungal susceptibility testing of Rhodotorula mucilaginosa. Eukaryot Cell 6:855– 867. https://doi.org/10.1111/j.1365-2958.2003.03790.x

14. Gerik KJ, Doering TL. 2003. Cell wall a-1,3-glucan is required to anchor Pbx proteins in Rhodotorula. J Exp Med 198:1685–1696. https://doi.org/10.1084/jem.198.2.1685

15. Cox GM, Mkherjee J, Cole GT, Casadevall A, Perfect JR. 2000. Urease as a virulence factor in experimental cryptococcosis. Infect Immun 68:434–448. https://doi.org/10.1128/IAI.68.2.434-448.2000

16. Salas SD, Bennett JE, Kwon-Chung KJ, Perfect JR, Williamson PR. 1996. Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med 184:377–386. https://doi.org/10.1084/jem.184.2.377

17. Zaragoza O, Casadevall A. 2003. Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO2. Infect Immun 71:6155 –6164. https://doi.org/10.1128/IAI.71.11.6155-6164.2003

18. Zaragoza O, Casadevall A. 2004. Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 6:10–15. https://doi.org/10.1251/bpo068

19. Reese AJ, Doering TL. 2003. Cell wall a-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol Microbiol 50:1401–1409. https://doi.org/10.1046/j.1365-2958.2003.03790.x

20. Reese AJ, Yoneda A, Breger JA, Beauvais A, Liu H, Griffith CL, Bose I, Kim M-J, Skau C, Yang S, Sejfo JA, Osumi M, Latge J-P, Mylonakis E, Doering TL. 2007. Loss of cell wall alpha(1-3) glucan affects Cryptococcus neoform-

21. Zaragoza O, Casadevall A. 2004. Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 6:10–15. https://doi.org/10.1251/bpo068

22. Reese AJ, Doering TL. 2003. Cell wall a-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol Microbiol 50:1401–1409. https://doi.org/10.1046/j.1365-2958.2003.03790.x

23. Zaragoza O, Casadevall A. 2004. Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 6:10–15. https://doi.org/10.1251/bpo068

24. Reese AJ, Doering TL. 2003. Cell wall a-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol Microbiol 50:1401–1409. https://doi.org/10.1046/j.1365-2958.2003.03790.x

25. Zaragoza O, Casadevall A. 2004. Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 6:10–15. https://doi.org/10.1251/bpo068

26. Reese AJ, Doering TL. 2003. Cell wall a-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol Microbiol 50:1401–1409. https://doi.org/10.1046/j.1365-2958.2003.03790.x
man from ultrastructure to virulence. Mol Microbiol 63:1385–1398. https://doi.org/10.1111/j.1365-2958.2006.05551.x.

33. Siafakas AR, Sorrell TC, Wright LC, Wilson C, Larsen M, Boadle R, Williamson PR, Djordjevic JT. 2007. Cell wall-linked cryptococcal phospholipase B1 is a source of secreted enzyme and a determinant of cell wall integrity. J Biol Chem 282:37508–37514. https://doi.org/10.1074/jbc.M707913200.

34. Simon MS, Somersan S, Singh HK, Hartman B, Wickes BL, Jenkins SG, Walsh TJ, Schuetz AN. 2014. Endocarditis caused by Rhodotorula infection. J Clin Microbiol 52:374–378. https://doi.org/10.1128/JCM.01950-13.

35. Schoch CL, Seifert KA, Huhndorf S, Robert V, Spouge JL, Levesque CA, Chen W, Fungal Barcoding Consortium. 2012. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for fungi. Proc Natl Acad Sci U S A 109:6241–6246. https://doi.org/10.1073/pnas.1117018109.

36. Vilgalys Mycology Lab. 2019. Conserved primer sequences for PCR amplification of fungal rDNA. https://sites.duke.edu/vilgalyslab/rdna Primers_for_fungi/.

37. Kimura M. 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16:111–120. https://doi.org/10.1007/BF01731581.

38. Kumar S, Stecher G, Tamura K. 2016. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Mol Biol Evol 33: 1870–1874. https://doi.org/10.1093/molbev/msw054.

39. Eisenman HC, Chow S-K, Tsé KK, McClelland EE, Casadevall A. 2011. The effect of L-DOPA on Cryptococcus neoformans growth and gene expression. Virulence 2:329–336. https://doi.org/10.4161/viru.2.4.16136.

40. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. https://doi.org/10.1038/nmeth.2019.

41. Chaplin MF, Kennedy JF (ed). 1994. Carbohydrate analysis: a practical approach. IRL Press, New York, NY.

42. de Brito Ximenes P, Beltrão EIC, Macêdo DPC, Buonafina MDS, de Lima-Neto RG, Neves RP. 2015. Targeting the Cryptococcus neoformans var. grubii cell wall using lectins: study of the carbohydrate-binding domain. Molecules 20:3776–3782. https://doi.org/10.3390/molecules20033776.